X

Trial Profile

PROMO: A Phase II Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Osteosarcoma
Focus Therapeutic Use
Acronyms PROMO

Most Recent Events

01 Sep 2021 Primary endpoint (Clinical benefit rate) has not been met, according to Results published in the Cancer Immunology Immunotherapy.
01 Sep 2021 Results published in the Cancer Immunology Immunotherapy
15 Oct 2020 According to clinicaltrials.gov the study was stopped because less than 2 patients had clinical benefit.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com